<DOC>
	<DOCNO>NCT01273844</DOCNO>
	<brief_summary>To evaluate efficacy safety Vel-Dex therapy ( bortezomib dexamethasone ) follow autologous hematopoietic stem cell transplantation initial treatment patient newly diagnose AL .</brief_summary>
	<brief_title>Study Bortezomib +HSCT Primary Systemic Amyloidosis ( AL )</brief_title>
	<detailed_description>Patients receive two 21-day cycle induction therapy vel / dex regimen . Bortezomib 1.3mg/m2 day 1 , 4 , 8 11 give intravenous bolus injection Dexamethasone 40 mg/d take orally day 1-4 . After two cycle vel / dex therapy , collection peripheral blood stem cell ( PBSC ) complete within 4 weeks.Patients receive ASCT therapy 8 week collection PBSC ( Recorded day 0 ) , melphalan ( day -2 ) dose 100,140 200 mg/m2 ( choose dose accord degree risk patient ) Vel 1mg/m2 ( day -6 , -3 , +1 , +4 ) give . Four additional 21-day cycle Vel treatment ( dose 1.6mg/m2 day 1 8 cycle ) conduct consolidation therapy recommend 60-90 day HSCT , resumption hematopoietic function ( neutrophil count &gt; 1.5x109/L platelet count &gt; 50x109/L ) . Later patient wo n't need maintenance therapy . The efficacy criterion international standard set consensus expert Tenth International Symposium Amyloid Amyloidosis .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>1 . Male female ; 2. aged 1865 year ; 3 . Patients newly diagnose AL ; 4 . Appropriate autologous hematopoietic stem cell transplantation ; 5 . Abnormal M protein free light chain detect serum / urine 6 . ECOG score 02 point ; 7 . Subjects ( legal representative ) must sign informed consent document indicate understand purpose procedure require study willingness participate study . 1 . Subjects receive systematic treatment steroid 2 . Subjects receive plasmapheresis treat clinical significant hyperviscosity syndrome within 4 week enrollment . 3 . Pregnant breastfeeding woman ; 4 . Subjects suffer multiple myeloma . 5. hypersensitivity dexamethasone , bortezomib , mannitol , boron , heparin ( use catheter ) ; 6 . Subjects severe cardiovascular disease , 7 . Subjects serious physical disease mental illness may interfere study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hematopoietic stem cell transplantation</keyword>
	<keyword>amyloidosis</keyword>
	<keyword>Bortezomib</keyword>
</DOC>